Perrigo (PRGO) Net Income towards Common Stockholders Growth (1y) (2013 - 2026)
Perrigo (PRGO) Net Income towards Common Stockholders Growth (1y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 68.18% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -0.17% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -388.62% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | -14.68% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 105.80% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 2,405.06% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -14.93% |
| 10 | Perrigo | 1.42 Bn | 1.06 Bn | 325.50 Mn | -33.85% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 28, 2026 | -33.85% |
| Dec 31, 2025 | -16.67% |
| Sep 27, 2025 | -52.94% |
| Jun 28, 2025 | -192.59% |
| Mar 29, 2025 | -209.52% |
| Dec 31, 2024 | 34.78% |
| Sep 28, 2024 | -183.33% |
| Jun 29, 2024 | -440.00% |
| Mar 30, 2024 | -10.53% |
| Dec 31, 2023 | 58.18% |
| Sep 30, 2023 | -144.44% |
| Jul 1, 2023 | -150.00% |
| Apr 1, 2023 | -72.73% |
| Dec 31, 2022 | 51.11% |
| Oct 1, 2022 | 154.00% |
| Jul 2, 2022 | -100.37% |
| Apr 2, 2022 | -103.12% |
| Dec 31, 2021 | 81.68% |
| Oct 2, 2021 | 97.24% |
| Jul 3, 2021 | 12.45% |